Etelcalcetide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Etelcalcetide. Educational only — not medical advice.
Labeled uses
PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Source: FDA labeling via NIH DailyMed (set cd270093…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.